Short answer
ResMed (RMD) filed an 8-K current report with the SEC on July 7, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). MatrixCare sale to Frazier Healthcare Partners for $490 million cash, expected closing in fiscal Q1 2027.
ResMed 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- MatrixCare sale to Frazier Healthcare Partners for $490 million cash, expected closing in fiscal Q1 2027
- MatrixCare contributed approximately $220 million revenue and $55 million non-GAAP operating profit in fiscal 2026
- Net proceeds targeted for shareholder returns, including an accelerated share repurchase, and general corporate purposes
- Noctrix acquisition expected to add approximately $30 million revenue but reduce fiscal 2027 non-GAAP diluted EPS by approximately $0.20
- Residential Care Software outlook maintained at high-single-digit fiscal 2027 revenue growth with operating leverage
Item 7.01 · Regulation FD Disclosure
- Item 7.01 incorporates the Item 2.02 earnings disclosure
- Investor relevance depends on the earnings release and related financial results in Item 2.02
Item EX-99.1 · Exhibit EX-99.1
- Definitive agreement to sell MatrixCare business to Frazier Healthcare Partners
- Divestiture covers MatrixCare, Healthcare First, Citus, and home health and hospice software
- MatrixCare serves more than 15,000 providers across post-acute and long-term care markets
- Excludes ResMed’s Brightree and MEDIFOX DAN software businesses
- Expected closing in ResMed’s fiscal Q1 2027, subject to regulatory approvals and customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ResMed 8-K filings
Get the next RMD 8-K as it lands
Follow RMD for push alerts, or ask the research agent what this filing means.